Physician profile
Barbara Searson
NPI 1215065065
$601.16
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $163 · 2020: $134 · 2021: $246 · 2022: $34.80 · 2024: $23.34.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $23.34.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $23.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $99.80 | 2019-2022 | |
| Aerie Pharmaceuticals, INC. | $86.13 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $78.15 | 2019-2021 | |
| Allergan, INC. | $76.16 | 2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $75.26 | 2021 | |
| Optos, INC. | $32.79 | 2020 | |
| Novartis Pharmaceuticals Corporation | $23.42 | 2020 | |
| Bausch & Lomb Americas INC. | $23.34 | 2024 | Envista Mx60 Iol |
| Kala Pharmaceuticals, INC. | $22.84 | 2021 | |
| Akorn, INC. | $18.96 | 2020 | |
| Glaukos Corporation | $17.66 | 2020 | |
| Ocular Therapeutix, INC. | $17.21 | 2020 | |
| Eyevance Pharmaceuticals LLC | $15.19 | 2019 | |
| Rxsight INC | $14.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Searson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.